
Bristol-Myers Squibb Reports Positive Phase 2 Results for Reblozyl in Alpha-Thalassemia
Bristol-Myers Squibb's Reblozyl achieved positive Phase 2 results for Alpha-Thalassemia, showing improved hemoglobin levels and reduced transfusion needs in patients.
BMYCELGrclinical trialdrug development